Phase 3 study of IPX066 for Parkinson's disease

April 20, 2009 - Impax Pharmaceuticals announced it has commenced a Phase 3 trial of IPX066 to treat Parkinson's disease (PD) based on encouraging interim data collected from its Phase 2 study in PD patients. This study, known as APEX-PD, will be the first of two Phase 3 studies and will include Parkinson's disease patients with mild symptoms of PD. Impax is planning to commence a second Phase 3 trial of IPX066 in patients with advanced PD patients later in 2009 or early 2010.

IPX066 is an investigational extended-release carbidopa-levodopa product designed to produce a fast and sustained concentration of levodopa, potentially improving PD clinical symptom management. Fonte: Empr.

__________________________________________________

Boehringer makes progress on Parkinson's treatment

Tuesday, February 23, 2010 - Boehringer Ingelheim Pharmaceuticals Inc. has made advances in its work on Parkinson's disease and sexual dysfunction amongst women.

The Ridgefield-based company Monday received approval from the Food and Drug Administration for an extended-release tablet for Mirapex ER, a medication used to treat early symptoms of Parkinson's. (segue...) Fonte: News Times.

Trata-se de dois medicamentos, carbidopa + levodopa (IPX066) e Pramipexole (Mirapex / Sifrol), ambos com liberação extendida/prolongada, em fase próxima de lançamento.